Towards Healthcare
Cellular Immunotherapy Market Drives by 22.45% CAGR till 2034

Cellular Immunotherapy Market 2025 North America to Lead Growth Amid Rising Cancer Cases and R&D Investments

Projections indicate that, the global cellular immunotherapy market will increase from USD 11.33 billion in 2024 to USD 85.78 billion by 2034, experiencing a CAGR of 22.45% over the next 10 years. The increasing investments in R&D activities, rapid advancements in cell engineering, supportive government framework, and rising prevalence of cancer are expected to drive the growth of the global cellular immunotherapy market over the forecast period.

Category: Therapeutic Area Insight Code: 5968 Format: PDF / PPT / Excel

Cellular Immunotherapy Market Size, Top Key Players with Growth and Segment Insights

The global cellular immunotherapy market size recorded US$ 11.33 billion in 2024, set to grow to US$ 13.87 billion in 2025 and projected to hit nearly US$ 85.78 billion by 2034, with a CAGR of 22.45% throughout the forecast timeline.

Cellular Immunotherapy Market Size 2024 to 2034

Cellular immunotherapy aligns with the rising trend towards personalized medicine, which enables the development of treatments tailored according to the individual patient profiles. The market is also expanding rapidly, driven by groundbreaking clinical outcomes, FDA/EMA approvals, and ongoing research into allogeneic (off-the-shelf) and in vivo cellular therapies that overcome the scalability and cost limitations of autologous products. In this global market, North America dominated the market, followed by Asia Pacific, fueled by the rising cancer burden, surge in government funding, and increasing presence of biotech hubs in China, Japan, and South Korea.

Key Takeaways

  • Cellular immunotherapy sector pushed the market to USD 11.33 billion by 2024.
  • Long-term projections show USD 85.78 billion valuation by 2034.
  • Growth is expected at a steady CAGR of 22.45% in between 2025 to 2034.
  • North America led the cellular immunotherapy market by capturing 54% share in 2024.
  • Asia Pacific is expected to be the fastest-growing region in the upcoming years.
  • By therapy type, the CAR-T Cell Therapy segment registered its dominance over the global market with a share of 61% in 2024.
  • By therapy type, the Natural Killer (NK) Cell Therapy segment is expected to grow with the highest CAGR in the market during the studied years.
  • By indication, the hematologic malignancies segment held the largest revenue share of 67% in the market in 2024.
  • By indication, the solid tumors segment is expected to show the fastest growth over the forecast period.
  • By cell source, the autologous (patient-derived cells) segment held a dominant presence in the cellular immunotherapy market with a share of 58% in 2024.
  • By cell source, the allogeneic (donor-derived cells) segment is expected to witness the fastest growth in the market over the forecast period.
  • By manufacturing modality, the ex vivo cell expansion segment contributed the biggest revenue share in the market in 2024.
  • By manufacturing modality, the in vivo engineering (via LNP, viral vectors, mRNA) segment is expected to grow at the fastest CAGR in the market during the forecast period.
  • By end user/application setting, the hospitals & cancer centers segment accounted for a maximum revenue share of 62% in the market in 2024.
  • By end user/application setting, the Contract Development & Manufacturing Organizations (CDMOs) segment is expected to expand rapidly in the market in the coming years.

Executive Summary Table

Metric Details
Market Size in 2025 USD 13.87 Billion
Projected Market Size in 2034 USD 85.78 Billion
CAGR (2025 - 2034) 22.45%
Leading Region North America Share 54%
Market Segmentation By Therapy Type, By Indication, By Cell Source, By Manufacturing Modality, By End User / Application Setting, By Region
Top Key Players Gilead Sciences (Kite Pharma), Novartis AG, Bristol Myers Squibb (BMS), Allogene Therapeutics, Adaptimmune Therapeutics, Sana Biotechnology, CRISPR Therapeutics, Fate Therapeutics, Autolus Therapeutics, Precision BioSciences, Poseida Therapeutics, Nkarta, Inc., Celyad Oncology, Caribou Biosciences, Immatics N.V., Bluebird Bio, Tessa Therapeutics, Beigene Ltd., Legend Biotech

Market Overview

The cellular immunotherapy market encompasses the development, manufacturing, and commercialization of therapeutic approaches that utilize living cells to stimulate or restore the body’s immune response against diseases, primarily cancer, but also infectious and autoimmune conditions. This includes T-cell therapies (CAR-T, TCR-T), Natural Killer (NK) cell therapies, Dendritic Cell (DC) therapies, and emerging macrophage-based therapies.

  • Acquisitions by key market players to strengthen their market position. For instance, in November 2024, Roche announced that it had entered into a definitive merger agreement to acquire Poseida Therapeutics, Inc., a public clinical-stage biopharmaceutical company pioneering donor-derived CAR-T cell therapies. Based in San Diego, California, Poseida’s R&D portfolio includes pre-clinical and clinical-stage off-the-shelf (also referred to as allogeneic) CAR-T therapies across several therapeutic areas, including haematological malignancies, solid tumours, and autoimmune disease, as well as manufacturing capabilities and technology platforms
  • In March 2025, PromiCell, a clinical-stage cellular immunotherapy company developing next-generation CAR T and TCR T cell therapies, launched its accredited investor-only investment campaign to accelerate the development of transformative cancer treatments. The company has secured exclusive technology licenses from Fred Hutchinson Cancer Research Center in Seattle and MSK. These partnerships enable PromiCell to accelerate clinical development, benefiting from world-class translational research, clinical trials, and cell processing expertise.

AI integration in the cellular immunotherapy market

The worldwide growing investments in AI technologies by many pharmaceutical companies to boost drug development and reach a market position are mainly impacting the widespread adoption of AI tools. Eventually, AI-powered measures give minimal expenses and time linked with drug discovery and development in both the chemical and biological sectors, with enhanced success rates in various clinical trial designs. In clinical trial optimization, AI has a crucial role in accelerating and improving trial design, patient recruitment, and monitoring. Whereas, in quality control, AI algorithms assist in automated data entry, analysis of vast datasets to resolve possible quality concerns, and estimate failures, with progressed product safety.

Market Dynamics

Driver

Rising Number of Cancers and Expanding Regulatory Approvals

The number of cancers and expanding regulatory approvals are expected to boost the growth of the cellular immunotherapy market during the forecast period. Cancer is one of the leading causes of death globally. In 2022, nearly 20 million new cancer cases were reported, and 9.7 million people died from the disease around the world. The surge in the incidence of cancer spurs the demand for cellular immunotherapy as an effective treatment approach. In addition, authorized regulatory bodies such as the U.S Food and Drug Administration (FDA) are expediting approvals for innovative cell-based therapies, bolstering the market’s expansion. Therefore, the rising number of product approvals and increasing prevalence of cancer has significantly adoption of these therapies.

  • In August 2024, the Food and Drug Administration (FDA) approved a cellular therapy called afamitresgene autoleucel, or afami-cel (Tecelra), to treat some people with metastatic synovial sarcoma, a type of soft tissue sarcoma. The decision marks the first time the agency has approved a treatment called a T-cell receptor (TCR) therapy for cancer.

Restraint

High Cost

The high cost associated with the cellular immunotherapy product manufacturing is anticipated to hamper the market's growth.  The manufacturing process is complicated and requires high capital investment, which often creates a barrier for small-scale industries and results in slow adoption in several low and middle-income countries. Such factors may hinder the growth of the global cellular immunotherapy market during the forecast period.

Opportunity

How are the Increasing Investments in Research and Development Impacting the Market Expansion?

The increasing focus on sustainability and eco-friendly products is projected to offer lucrative growth opportunities to the dispenser pump market in the coming years. The market has witnessed a surge in heavy investment in research and development by robust pharmaceutical and biotechnology companies to expand novel cellular-based treatment approaches. Significant funding from both the private and government sectors is supporting cancer treatment through research grants and initiatives, further encouraging the development and adoption of cellular immunotherapies.

  • In March 2025, IDIBAPS launched an AECC-funded excellence programme to improve the response to immunotherapy in cancer. Funded by the Spanish Association Against Cancer (AECC), the project has a budget of 2 million euros and is expected to last four years.

Segmental Insights

Which Cell Source Led the Cellular Immunotherapy Market in 2024?

In 2024, the autologous (patient-derived cells) segment registered dominance. Autologous cell therapies are being widely explored for cancer. These therapies, which utilize a patient's cells and are highly preferred for their reduced risk of rejection as compared to the allogeneic approach. Moreover, several regulatory bodies, like the EMA and FDA, are increasingly recognizing the significance of these advanced therapies and streamlining approval processes.

 On the other hand, the allogeneic (donor-derived cells) segment is expected to witness the fastest growth in the market over the forecast period, owing to the rising incidence of cancer. Allogeneic therapies are readily available, "off-the-shelf" products and are less expensive than autologous therapies, potentially reducing cancer treatment delays and costs.

What causes the ex vivo cell expansion segment to dominate the market in 2024?

The ex vivo cell expansion segment was dominant, with the biggest share of the global cellular immunotherapy market in 2024. In ex vivo cell expansion, patients' immune cells are isolated, activated, and multiplied in a lab setting before being reinfused into the patient’s body. Ex vivo cell expansion is a crucial part of cellular immunotherapy, fuelling the production of effective and persistent immune cell therapies to fight against cancer.

On the other hand, the in vivo engineering (via LNP, viral vectors, mRNA) segment is expected to register the fastest growth, owing to the increasing need for treating various diseases, including cancer. In vivo engineering is the process of modifying immune cells directly within the body rather than outside the body in a lab. In vivo engineering is a cost-effective, accessible, and significantly safer cellular immunotherapy.

Why did the CAR-T Cell Therapy segment hold the largest share in 2024?

The CAR-T Cell Therapy segment led the cellular immunotherapy market in 2024. CAR T-cell therapy is a prominent type of cancer immunotherapy that uses a patient's own genetically modified immune cells to destroy cancer. CAR-T therapies have significantly revolutionized the treatment of cancers. Currently, there are several CAR T-cell therapy trials underway for various cancers. The growth of the segment is driven by the rising prevalence of cancer, a surge in clinical trial success rates, rising regulatory approvals, increasing investments by biotechnology companies, and growing demand for personalized medicine.

  • In January 2025, India’s Central Drugs Standard Control Organization (CDSCO) approved varnimcabtagene autoleucel (var-cel), a CD19-targeted chimeric antigen receptor (CAR) T-cell therapy, to treat adult patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

On the other hand, the Natural Killer (NK) Cell Therapy segment is anticipated to register rapid expansion in the predicted timeframe. The growth of the segment is fuelled by the growing need for effective cancer treatments, rising investments in research and development, and rapid technological advancements in cell engineering, particularly with techniques like CRISPR-Cas9. Natural killer (NK) cell therapeutics leverage the body’s immune system to fight cancer without prior sensitization. NK cells can recognize and destroy abnormal cells in the body. These cell therapies can use allogeneic (donor-derived) NK cells. NK cell therapies offer a promising and transformative treatment option for a wider range of cancer patients.

  • In April 2024, Ingenium Therapeutics, a leading innovator in next-generation NK cell therapies, announced that its investigational therapy IGNK001 (Gengluecel) has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML).

By End User/Application Setting

The hospitals & cancer centers segment accounted for a maximum revenue share of 62% in the market in 2024. The increasing incidence of cancer has substantially increased the total number of hospitalizations globally in hospital settings. Cancer institutes are increasingly offering advanced treatment and care to a high number of cancer patients. Additionally, hospitals & cancer centers are equipped with the necessary infrastructure and highly skilled healthcare professionals to deliver advanced cancer treatments, including cellular immunotherapy.

  • In September 2024, Amrita Hospital, Faridabad, unveiled a Centre of Excellence (CoE) for CAR T-cell therapy, aimed at offering cutting-edge cancer treatments to patients in the National Capital Region (NCR). The center is dedicated to administering CAR T-cell therapy, an advanced immunotherapy (gene-modified T-cells) designed to treat specific blood cancers, including B-cell non-Hodgkin lymphomas and acute lymphoblastic leukemia.

On the other hand, the Contract Development & Manufacturing Organizations (CDMOs) segment is expected to expand rapidly in the market in the coming years. Biotechnology and pharmaceutical companies are increasingly relying on CDMOs to handle various aspects of cellular-based therapy development and manufacturing, which allows them to focus on core activities. The potential of cellular immunotherapy to offer personalized and curative treatments in oncology creates significant opportunities for CDMOs to provide specialized manufacturing services.

Which indication was dominant in the market in 2024?

  • In the cellular immunotherapy market, the hematologic malignancies segment held a major share in 2024. The growth of the segment is attributed to the high cellular immunotherapy product penetration for the treatment of hematologic malignancies. Hematologic malignancies are cancers that affect blood, bone marrow, and lymph nodes. Haematological malignancies are the most common cancer group in economically developed regions of the world. Hematologic cancers are generally classified into three categories such as lymphoma, leukemia, and multiple myeloma.
  • According to the article published by The Lancet, Haematologic malignancies accounted for 6.6% of total cancer cases and 7.2% of total cancer-related deaths worldwide in 2022.
  • Globally, the total number of hematological malignancy cases is projected to reach approximately 4,634,937. The projected total number of hematological malignancy cases by 2030 across different levels of SDI is as follows: 1,113,313 cases in high-SDI areas, 1,004,403 cases in high-middle SDI areas, 475,496 cases in low-SDI areas, 795,475 cases in low-middle SDI areas, and 1,244,424 cases in middle-SDI areas.
  • On the other hand, the solid tumors are predicted to expand fastest in the coming era. An abnormal mass of tissue that usually does not contain cysts or liquid areas. Solid tumors can occur anywhere in the body, including in muscles, bones, and organs. The most common type of solid tumor is found in the brain. Cellular immunotherapy offers a promising approach and is an effective treatment against solid tumors.

Regional Insights

Cellular Immunotherapy Market Share, By Region, 2024 (%)

What Made North America Dominate the Market in 2024?

A major revenue share captured by North America in the cellular immunotherapy market share by 54% in 2024. This region holds a strong position in the cellular immunotherapy market, with the presence of a thriving biotechnology sector, accelerating emphasis on healthcare spending, surging R&D investments by key players, and increasing regulatory approvals. The rising prevalence of cancer, along with the development of advanced cell-based therapies, is expected to boost the market’s revenue during the forecast period.

The U.S. Cellular Immunotherapy Market Trends

The country has a well-established healthcare infrastructure, a robust presence of key biotechnology companies, increasing availability of advanced therapies, and high per capita healthcare expenditure. The key players are actively involved in research & development and manufacturing of cellular immunotherapies, including CAR-T cells, NK cells, and other immune cell types.  The increasing prevalence of cancer has significantly contributed to the dominance of the market in the region.

  • According to the data published by the American Cancer Society in April 2025, in total, 2,041,910 new cancer diagnoses are expected in 2025; this represents approximately 5600 cases every day. For men, the total number of estimated new cancer cases in 2025 for all sites is 1,053,250, with prostate, lung/bronchus, and colorectal cancer accounting for nearly half (48%) of all diagnoses.

Regulatory bodies such as the FDA are expediting approvals for advanced cell-based therapies, driving the segment’s growth. The FDA is offering rapid approval pathways with rigorous safety evaluations, which facilitate the introduction of novel treatments. Moreover, the ongoing clinical trials and research efforts are substantially expanding the applications of cellular immunotherapies in the country.

  • In May 2025, an international clinical trial led by WashU Medicine researchers showed that an innovative CAR-T cell immunotherapy is promising against aggressive T cell cancers and has manageable side effects. Armin Ghobadi, MD, prepares the new “universal” CAR-T cell product for a patient’s infusion as part of a clinical trial at Siteman Cancer Center, based at Barnes-Jewish Hospital and WashU Medicine.

The Canadian Cellular Immunotherapy Market Trends

In this country, the rise in healthcare expenditure, coupled with an increasing number of cancers, has significantly contributed to the dominance of the market in the region. Several key participants in the country are expanding capacity to meet the demand for advanced cancer therapy. The rise in clinical trials, surging investment in R&D activities, rising advancement in cell engineering techniques, and growing demand for personalized (allogeneic, off-the-shelf) treatments, propelling the growth of the cellular immunotherapy market in the country.

Which Factors are Going to Play a Crucial Role in the Asia Pacific Expansion?

During 2025-2034 in the cellular immunotherapy market, the Asia Pacific market is expanding steadily, attributed to the high incidences of cancer, rapid advancements in cell engineering, increasing funding for cell-based research, favorable reimbursement policies, expanding regulatory approval, and a growing focus on precision medicine. Moreover, the greater R&D spending by major players and the increasing number of clinical studies are likely to boost the expansion of the cellular immunotherapy market in the region. The rising progress in technology and the need for cell-based approaches in cancer therapy, driving the market’s growth. Several key players in the market are strategically adopting initiatives such as mergers & acquisitions and product launches to strengthen their market presence.

India Cellular Immunotherapy Market Trends

The country has a rapidly developing healthcare infrastructure, surging investment in the development of availability of advanced cancer therapies, and the availability of specialized healthcare professionals. Governments in the country are increasingly prioritizing the biotechnology sector and supporting the development of cellular immunotherapy through various initiatives. Key players in the market continue to offer advanced cellular immunotherapy to meet the rising need for cancer treatment.

  • According to the article published by the Press Information Bureau (PIB) in February 2025, in India, around 100 out of every 1 lakh people are diagnosed with cancer. According to the Indian Council of Medical Research (ICMR), the estimated number of incidences of cancer cases was more than 14 lakhs in 2023 in India.

The China Cellular Immunotherapy Market Trends

The country has a sophisticated healthcare infrastructure and high per capita healthcare expenditure. The country has the presence of a strong research infrastructure, along with a large number of clinical studies being conducted by cell therapy manufacturers, which has significantly contributed to the growth of the market. Government support through research grants and initiatives significantly encourages the development and adoption of cellular immunotherapies in the country.

  • According to the article published by the American Society of Hematology in November 2023, China is expected to face a considerable surge in the total number of hematological malignancy cases, with an estimate of approximately 859,692 cases by 2030.

Top Companies in the Cellular Immunotherapy Market

Cellular Immunotherapy Market Companies

  • Gilead Sciences (Kite Pharma)
  • Novartis AG
  • Bristol Myers Squibb (BMS)
  • Allogene Therapeutics
  • Adaptimmune Therapeutics
  • Sana Biotechnology
  • CRISPR Therapeutics
  • Fate Therapeutics
  • Autolus Therapeutics
  • Precision BioSciences
  • Poseida Therapeutics
  • Nkarta, Inc.
  • Celyad Oncology
  • Caribou Biosciences
  • Immatics N.V.
  • Bluebird Bio
  • Tessa Therapeutics
  • Beigene Ltd.
  • Legend Biotech

Latest Announcements by Industry Leaders

In December 2024, Tampa General Hospital (TGH) announced the opening of a new outpatient Cellular-Immunotherapy Transplant Unit (CTU) at the TGH Cancer Institute to offer alternative cell therapy treatment to patients with aggressive blood cancers such as leukemias, lymphomas, multiple myeloma, and other cancers. The program allows adult patients undergoing Chimeric Antigen Receptor (CAR) T-cell therapy and Bone Marrow Transplant (BMT) to receive daily treatment at the new unit as an outpatient while living at home with a 24/7 caregiver to monitor the patient, take vitals, and communicate regularly with TGH clinicians on the patient's behalf.

Recent Developments

  • In December 2024, Cimeio Therapeutics entered a research collaboration with Kyowa Kirin Co., Ltd. (Kyowa Kirin) to develop a novel therapy for diseases with high unmet need. The partnership combines Cimeio’s proprietary Shielded-Cell & Immunotherapy Pairs (SCIP) platform with Kyowa Kirin’s expertise in cellular therapies and underscores both companies’ commitment to using emerging cell and gene therapy technologies to develop new ways to treat patients.
  • In September 2024, Vironexis Biotherapeutics, focused on transforming the future of cancer treatment by pioneering AAV-delivered T-cell immunotherapy, unveiled its TransJoin AAV Gene Therapy Platform and a pipeline of more than ten product candidates for blood-based cancers, solid tumor metastasis prevention, and a cancer vaccine

Segments Covered in the Report

By Therapy Type

  • CAR-T Cell Therapy
    • FDA-approved products: Yescarta, Kymriah, Abecma, Carvykti
  • TCR-T Cell Therapy
    • Targets intracellular antigens (e.g., NY-ESO-1, MAGE-A4)
  • Natural Killer (NK) Cell Therapy (Fastest Growing)
    • Allogeneic and off-the-shelf NK cell products
  • Dendritic Cell Therapy
    • Used in prostate cancer and under development for others
  • Macrophage-Based and Other Cell Therapies
    • Experimental stage with potential in solid tumors

By Indication

  • Hematologic Malignancies
    • Lymphoma, Leukemia, Multiple Myeloma
  • Solid Tumors
    • Glioblastoma, Melanoma, Ovarian, Lung
  • Infectious Diseases
    • CMV, EBV, COVID-19, HIV (emerging)
  • Autoimmune Diseases
    • Lupus, Type 1 diabetes, Multiple sclerosis (early-phase trials)

By Cell Source

  • Autologous (Patient-Derived Cells)
    • Personalized, but costly and logistically complex
  • Allogeneic (Donor-Derived Cells) (Fastest Growing)
    • "Off-the-shelf" therapies using gene editing to reduce rejection
  • Stem Cell-Derived Immune Cells
    • iPSC-derived T, NK, or DC cells
  • In Vivo Cell Engineering (Emerging)
    • Delivery of CAR/TCR instructions directly to cells inside the body

By Manufacturing Modality

  • Ex Vivo Cell Expansion
    • Most current FDA-approved products
  • In Vivo Engineering (via LNP, viral vectors, mRNA)
  • Modular Bioreactor-Based Manufacturing
  • Automated Closed-System Manufacturing

By End User / Application Setting

  • Hospitals & Cancer Centers
  • Academic Research Institutes
  • Contract Development & Manufacturing Organizations (CDMOs)
  • Specialized Immunotherapy Clinics
  • Biotech/Pharma R&D Settings

By Region 

  • North America
    • U.S.
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Thailand
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Sweden
    • Denmark
    • Norway
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • UAE
    • Saudi Arabia
    • Kuwait
  • Last Updated: 08 August 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

Meet the Team

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology and healthcare services.

Learn more about Deepa Pandey

Aditi Shivarkar, with over 14 years of experience in consumer goods, leads research at Towards Consumer Goods, ensuring precise, actionable insights on trends, consumer preferences, and sustainable packaging for businesses.

Learn more about Aditi Shivarkar

Related Reports

FAQ's

The cellular immunotherapy market is projected to reach USD 85.78 billion by 2034, growing at a CAGR of 22.45% from 2024 to 2034.

he cellular immunotherapy market encompasses the development, manufacturing, and commercialization of therapeutic approaches that utilize living cells to stimulate or restore the body immune response against diseases, primarily cancer, but also infectious and autoimmune conditions. This includes T-cell therapies (CAR-T, TCR-T), Natural Killer (NK) cell therapies, Dendritic Cell (DC) therapies, and emerging macrophage-based therapies.

North America is expected to dominate the plastic caps market, followed by Asia Pacific.

The key drivers that mainly boost the market growth include increasing investments in R&D activities, growing demand for personalized medicine, rapid advancements in cell engineering, a supportive government framework, and the rising prevalence of cancer.

The key players include Gilead Sciences, Novartis AG, Bristol Myers Squibb (BMS), Johnson & Johnson + Legend Biotech, Allogene Therapeutics, Adaptimmune Therapeutics, Sana Biotechnology, CRISPR Therapeutics, Fate Therapeutics, Autolus Therapeutics, Precision BioSciences, Poseida Therapeutics, Nkarta, Inc., Celyad Oncology, Caribou Biosciences, Immatics N.V., Tessa Therapeutics, Beigene Ltd., and others.